Artery Research
Volume 2, Issue 4 , Pages 138-147 , November 2008

A cardiovascular phenotype in warfarin-resistant Vkorc1 mutant rats

  • Michael H. Kohn

      Affiliations

    • Department of Ecology and Evolutionary Biology, Institute of Biosciences and Bioengineering, Rice University, MS 170, 6100 Main Street, Houston, TX 77005, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 713 348 3779; fax: +1 713 348 5232.
    • ,
  • Roger E. Price

      Affiliations

    • Comparative Pathology Laboratory, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    • ,
  • Hans-Joachim Pelz

      Affiliations

    • Federal Research Centre for Cultivated Plants, Julius Kuehn Institute, Vertebrate Research, Toppheideweg 88, Münster 48161, Germany

Received 11 July 2008 ,Revised 26 August 2008 ,Accepted 22 September 2008.

References 

  1. Stahmann MA, Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent. J Biol Chem. 1941;138(5):513–527
  2. Boyle CM. Case of apparent resistance of Rattus norvegicus Berkenhout to anticoagulant poisons. Nature. 1960;188:517
  3. Lund M. Resistance to warfarin in common rat. Nature. 1964;203(494):778
  4. Greaves JH, Ayres P. Heritable resistance to warfarin in rats. Nature. 1967;215(5103):877–878
  5. Bell RG, Caldwell PT. Mechanism of warfarin resistance – metabolism of vitamin-K1. Biochemistry. 1973;12(9):1759–1762
  6. Fasco MJ, Hildebrandt EF, Suttie JW. Evidence that warfarin anticoagulant action involves two distinct reductase activities. J Biol Chem. 1982;257(19):11210–11212
  7. Hildebrandt EF, Preusch PC, Patterson JL, Suttie JW. Solubilization and characterization of vitamin K epoxide reductase from normal and warfarin-resistant rat liver microsomes. Arch Biochem Biophys. 1984;228(2):480–492
  8. MacNicoll AD. A comparison of warfarin resistance and liver microsomal vitamin K epoxide reductase activity in rats. Biochim Biophys Acta. 1985;840(1):13–20
  9. Kohn MH, Pelz JH. Genomic assignment of the warfarin resistance locus, Rw, in the rat. Mamm Genome. 1999;10(7):696–698
  10. Kohn MH, Pelz HJ. A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans. Blood. 2000;96(5):1996–1998
  11. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz H-J, et al. Mutations in Vkorc1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427(6974):537–541
  12. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature. 2004;427(6974):541–544
  13. Wallin R, Hutson SM. Warfarin and the vitamin K-dependent gamma-carboxylation system. Trends Mol Med. 2004;10(7):299–302
  14. Stafford DW. The vitamin K cycle. J Thromb Haemost. 2005;3(8):1873–1878
  15. Suttie JW. Warfarin and vitamin-K. Clin Cardiol. 1990;13(4):16–18
  16. Scully MF. Warfarin therapy: rat poison and the prevention of thrombosis. The Biochemist. 2002;24:15–17
  17. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the Vkorc1 gene is associated with an interindividual variability in the dose–anticoagulant effect of warfarin. Blood. 2005;105(2):645–649
  18. Li T, Lange LA, Li X, Susswein L, Bryant B, Malone R, et al. Polymorphisms in the Vkorc1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet. 2006;43(9):740–744
  19. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis. 2008;25:45–51
  20. Schurgers LJ, Aebert H, Vermeer C, Bultmann B, Janzen J. Oral anticoagulant treatment: friend or foe in cardiovascular disease?. Blood. 2004;104(10):3231–3232
  21. Fregin A, Rost S, Wolz W, Krebsova A, Muller CR, Oldenburg J. Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16. Blood. 2002;100(9):3229–3232
  22. Pelz HJ, Rost S, Hunerberg M, Fregin A, Heiberg AC, Baert K, et al. The genetic basis of resistance to anticoagulants in rodents. Genetics. 2005;170(4):1839–1847
  23. Schurgers LJ, Dissel PE, Spronk HM, Soute BA, Dhore CR, Cleutjens JP, et al. Role of vitamin K and vitamin K-dependent proteins in vascular calcification. Z Kardiol. 2001;90(Suppl. 3):III/57–III/63
  24. Price PA, Faus SA, Williamson MK. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol. 2000;20(2):317–327
  25. Shearer MJ. Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care. 2000;3(6):433–438
  26. Price PA, Buckley JR, June HH, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. J Bone Miner Res. 2001;16:S157–S158
  27. Wallin R, Wajih N, Greenwood GT, Sane DC. Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev. 2001;21(4):274–301
  28. Erkkila AT, Booth SL. Vitamin K intake and atherosclerosis. Curr Opin Lipidol. 2008;19:39–42
  29. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol. 1998;18(9):1400–1407
  30. Howe AM, Webster WS. Warfarin exposure and calcification of the arterial system in the rat. Int J Exp Pathol. 2000;81(1):51–56
  31. Price PA, Patel R, Alagao FC. Matrix Gla protein specifically inhibits calcification of human aortic elastin in vitro. Arterioscler Thromb Vasc Biol. 2001;21(4):703–708
  32. Shanahan CM, Proudfoot D, Farzaneh-Far A, Weissberg PL. The role of Gla proteins in vascular calcification. Crit Rev Eukaryot Gene Expr. 1998;8(3–4):357–375
  33. Alagao FC, Patel R, Price PA. Matrix Gla protein specifically inhibits calcification of human aortic elastin in vitro. J Bone Miner Res. 2000;15:S208
  34. Bostrom K, Demer LL. Regulatory mechanisms in vascular calcification. Crit Rev Eukaryot Gene Expr. 2000;10(2):151–158
  35. Braam L, Dissel P, Gijsbers B, Spronk HMH, Hamulyak K, Soute BAM, et al. Assay for human matrix Gla protein in serum – potential applications in the cardiovascular field. Arterioscler Thromb Vasc Biol. 2000;20(5):1257–1261
  36. Canfield AE, Doherty MJ, Kelly V, Newman B, Farrington C, Grant ME, et al. Matrix Gla protein is differentially expressed during the deposition of a calcified matrix by vascular pericytes. FEBS Lett. 2000;487(2):267–271
  37. Wallin R, Cain D, Hutson SM, Sane DC, Loeser R. Modulation of the binding of matrix Gla protein (MGP) to bone morphogenetic protein-2 (BMP-2). Thromb Haemost. 2000;84(6):1039–1044
  38. Dhore C, Cleutjens J, Kitslaar P, Tordoir J, Soute B, Vermeer C, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21(12):1998–2003
  39. Farzaneh-Far A, Weissberg PL, Proudfoot D, Shanahan CM. Transcriptional regulation of matrix Gla protein. Z Kardiol. 2001;90(Suppl. 3):38–42
  40. Wang Y, Bostrom KI. Matrix Gla protein binds bone morphogenetic protein-2, possible mechanism in vascular calcification. Arterioscler Thromb Vasc Biol. 2001;21(4):702–708
  41. Whittaker P, Donovan JL, Przyklenk K. Long-term warfarin therapy is associated with tissue calcification. J Thromb Thrombolysis. 2008;25:125–128
  42. Herrmann SM, Whatling C, Brand E, Nicaud V, Gariepy J, Simon A, et al. Genetic polymorphisms in the matrix Gla protein are associated with calcification, atherosclerosis and myocardial infarction. Nieren Hochdruck. 2001;30(5):193–195
  43. Wang YB, Zhang WL, Zhang YH, Yang YJ, Sun LZ, Hu SS, et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation. 2006;113(12):1615–1621
  44. Jackson WB. Case histories of anticoagulant resistance. In: Committee on Strategies for the Management of Pesticide Resistant Pest Populations, National Research Council, editor. Pesticide resistance strategies and tactics for management. Washington DC: National Academy Press; 1986;
  45. Pelz HJ, Rost S, Muller CR. DNA-based field monitoring of warfarin resistance in rats (Rattus norvegicus). Intl J Pest Management. 2007;53:281–284
  46. Bishop JA, Hartley DJ, Partridge GG. Population-dynamics of genetically determined resistance to warfarin in Rattus norvegicus from Mid Wales. Heredity. 1977;39(12):389–398
  47. Partridge GG. Relative fitness of genotypes in a population of Rattus norvegicus polymorphic for warfarin resistance. Heredity. 1979;43(10):239–246
  48. Berdoy M, Smith P. Arms-race and rat race – adaptations against poisoning in the brown rat. Rev Ecol-Terre Vie. 1993;48(2):215–228
  49. Kohn MH, Pelz HJ, Wayne RK. Natural selection mapping of the warfarin-resistance gene. Proc Natl Acad Sci U S A. 2000;97(14):7911–7915
  50. Greaves JH, Ayres PB. Unifactorial inheritance of warfarin resistance in Rattus norvegicus from Denmark. Genet Res. 1977;29(3):215–222
  51. Smith P, Townsend MG, Smith RH. A cost of resistance in the brown rat – reduced growth-rate in warfarin-resistant lines. Funct Ecol. 1991;5(3):441–447
  52. Partridge GG. The vitamin-K requirements of wild Brown rats (Rattus norvegicus) resistant to warfarin. Comp Biochem Physiol. 1980;66(1):3–7
  53. Greaves JH, Redfern R, Ayres PB, Gill JE. Warfarin resistance – balanced polymorphism in Norway rat. Genet Res. 1977;30(3):257–263
  54. Smith P, Berdoy M, Smith RH. Body-weight and social dominance in anticoagulant-resistant rats. Crop Prot. 1994;13(4):311–315
  55. Pelz HJ, Hanisch D, Lauenstein G. Resistance to anticoagulant rodenticides in Germany and future strategies to control Rattus norvegicus. Pestic Sci. 1995;43(1):61–67
  56. Pelz HJ, Klemann N. Rat control strategies in organic pig and poultry production with special reference to rodenticide resistance and feeding behaviour. Njas-Wageningen J Life Sci. 2004;52(2):173–184
  57. Rost S, Fregin A, Hunerberg M, Bevans CG, Muller CR, Oldenburg J. Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1—evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin. Thromb Haemost. 2005;94(4):780–786
  58. Kohn MH, Pelz HJ, Wayne RK. Locus-specific genetic differentiation at Rw among warfarin-resistant rat (Rattus norvegicus) populations. Genetics. 2003;164(3):1055–1070
  59. Yasui T, Fujita K, Sasaki S, Sato M, Sugimoto M, Hirota S, et al. Expression of bone matrix proteins in urolithiasis model rats. Urol Res. 1999;27(4):255–261
  60. Greaves JH, Ayres PB. Multiple allelism at the locus controlling warfarin resistance in the Norway rat. Genet Res. 1982;40(1):59–64
  61. Smith P, Berdoy M, Smith RH, Macdonald DW. A new aspect of warfarin resistance in wild rats – benefits in the absence of poison. Funct Ecol. 1993;7(2):190–194
  62. Markussen MDK, Heiberg AC, Nielsen R, Leirs H. Vitamin K requirement in Danish anticoagulant-resistant Norway rats (Rattus norvegicus). Pest Manag Sci. 2003;59(8):913–920

☆ Grant support: Hamill Innovation grant; and National Heart, Lung, and Blood Institute (NHLBI).

PII: S1872-9312(08)00505-X

doi: 10.1016/j.artres.2008.09.002

Artery Research
Volume 2, Issue 4 , Pages 138-147 , November 2008

Article Tools

* Image Usage & Resolution